BCL9 and ductal breast carcinoma in situ: BCL9 gene expression was significantly increased at 10 compared to 2 weeks in both SUM225 and DCIS.COM MIND xenografts (62 ± 14 and 35 ± 12 fold increase, respectively; mean ± SEM p <0.05) (Fig. 3a, b).